BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. SLC12A1, Coagulation, Pseudomonas infection, Embryo, DNA fingerprint, Ciprofibrate)
Bookmark Forward

QuickView for Medullary thyroid carcinoma (phenotype)


Genetic Markers

Most Correlated Genes

Most Correlated SNPs

  1. RET
  2. TCO
  3. NTRK1
  4. CALCB
  5. CALCA
  1. No SNPs found
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. locomotion
  2. signaling receptor activity
  3. vesicle
  4. axon
  5. neuron projection
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Medullary thyroid cancer TT cell line treated with FAK inhibitors - Y15 or PF04554878
  2. Thyroid adenomas and carcinomas expression profiles
  3. OMIM - Thyroid disease
  4. OMIM - Cancer
  5. Thyroid cancer TT and MZ-CRC-1 cells treated with dinaciclib
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Medullary thyroid carcinoma in children].
  2. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 pati…
  3. An unusual combination of parathyroid adenoma, medullary and papillary thyroid carcinoma.
  4. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
  5. Extent of surgery in clinically evident but operable MTC - when is central and/or lateral lympadenec…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
  2. Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Different…
  3. Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
  4. An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
  5. Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Explore Clinical Trials Results
  • Copyright © 2023 Illumina Inc. All rights reserved.